Good points. In a stable market it would be easier to go it alone. But our ph3 has a bit to play out before they make an investment decision. Sounds like FDA want more information on Lag3 method of action before making a recommendation. And what they have to say will determine how this plays out. Note that the EMA didn’t specifically endorse a ph3 they just endorsed our clinical program, not sure if that means anything.
On balance now without a significant recovery in the share price you’d have to assume they would need a partner for AIPAC
Good points. In a stable market it would be easier to go it...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.3¢ |
Change
-0.003(0.88%) |
Mkt cap ! $413.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 27.5¢ | $609.6K | 2.178M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 260786 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 226102 | 15 |
View Market Depth
| Last trade - 11.26am 04/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |